H.C. Wainwright lowered the firm’s price target on Day One Biopharmaceuticals (DAWN) to $36 from $40 and keeps a Buy rating on the shares. The firm refined its Ojemda sales trajectory to better reflect the growth trends observed in 2024.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DAWN:
- Buy Rating Affirmed for Day One Biopharmaceuticals: Strategic Growth and Pipeline Expansion Drive Positive Outlook
- Day One Biopharmaceuticals Reports Strong 2024 Results
- Promising Growth and Strategic Positioning Justify Buy Rating for Day One Biopharmaceuticals
- Day One Biopharmaceuticals Reports 2024 Financial Results
- Day One Biopharmaceuticals reports Q4 EPS ($1.02), consensus (35c)